DYDanila V. Yudakov

Danila V. Yudakov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Danila V. Yudakov has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Chronological patterns of lacrimal drainage obstruction following radioactive iodine therapy for differentiated thyroid cancer

    by V.D. Yartsev, E.L. Atkova, E.A. Ushakov, A.A. Trukhin, D.V. Yudakov, S.V. Grishkov, M.S. Sheremeta, M.A. Efremenko, P.N. Ilina

    Radioactive iodine (I-131) therapy for differentiated thyroid cancer is associated with a risk of delayed complications affecting radiosensitive organs. One such complication is secondary obstruction of the lacrimal drainage system caused by accumulation of I-131 in the wall of the nasolacrimal duct, leading to chronic inflammation and fibrosis. However, the precise chronological pattern of this pathology’s onset remains undefined. Purpose. This study investigated the chronological patterns of lacrimal drainage obstruction following radioactive iodine therapy. Material and Methods. This retrospective survey involved 375 patients who underwent a single course of radioactive iodine therapy between 2021 and 2025. The patients were stratified into five groups according to the time interval between therapy and survey: ≤6; 7—12; 13—24; 25—36; and 37—51 months. Obstruction was defined as epiphora graded 3—4 on the Munk scale. Statistical analysis included Pearson’s χ² test, Fisher’s exact test, and linear trend analysis (p<0.05 was considered significant). Results. No cases of lacrimal drainage obstruction were identified within the first 6 months after therapy, then the frequency of complications increased progressively: 6.3% (7—12 months), 11.3% (13—24 months), and 13.6% (25—36 months), followed by a decrease to 7.5% (37—51 months). The association with time since radioactive iodine therapy was statistically significant (p=0.014; p=0.002). After 6 months, the association lost statistical significance (p=0.455), indicating risk stabilization. The probability of obstruction was significantly higher in men (χ²=5.637; p=0.018). The administered activity of I-131 had no statistically significant impact. Conclusion. Lacrimal drainage obstruction is a delayed complication of radioactive iodine therapy for differentiated thyroid cancer, with a peak incidence at 25—36 months after treatment. The critical screening period is 6—51 months post-therapy. Early diagnosis and timely referral to an ophthalmologist improve the effectiveness of minimally invasive interventions.

  • Open Access

    The system of accounting and control of dose loads on the lacrimal apparatus during radiotherapy of thyroid cancer

    by Danila V. Yudakov, Alexey A. Trukhin, Marina S. Sheremeta, Anatoliy S. Makeev, Vasiliy D. Yartsev, Трухин Алексей Андреевич, Ярцев Василий Дмитриевич

    BACKGROUND: Lacrimal glands and lacrimal pathways are one of the main undesirable targets during radionuclide therapy using I-131, namely, in 24% of cases, secondary lacrimal pathways obliteration occurs [1]. In the legislation of the Russian Federation in the field of atomic energy use, there are a number of administrative documents obliging to keep records and control of individual radiation doses with the provision of data to the unified system for monitoring individual radiation doses of citizens. At the same time, statistical analysis does not include systematic accounting and control of individual doses of internal radiation to patients, in particular, to the lacrimal apparatus, when using nuclear medicine methods for therapeutic purposes. AIM: To develop a software and hardware preventive complex — a system for accounting and monitoring dose loads on lacrimal pathways during radioiodotherapy. MATERIALS AND METHODS: GE Discovery NM/CT 670 imaging systems, GE Discovery NM 630, the Xeleris 4 DR Workstation nuclear Medicine Workstation and the I-131-based radioisotope were used. To exclude the ingress of radioisotope into lacrimal pathways, the use of vasoconstrictive drugs and the use of tear point obturators were considered. The client part of the web service was implemented based on the React JavaScript library. The development of the Backend component was carried out in the Python programming language. RESULTS: To assess the risk of complications, a method was developed that takes into account the following parameters: age, gender, total administered activity to the patient, the presence of current lacrimation at the time of hospitalization, the presence of menopause (for women) and the accumulation index I-131 in lacrimal pathways. The primary data (anamnesis and prescribed treatment) are entered by the patient's attending physician in the questionnaire during the initial examination. At 72 hours after the introduction of radioisotope, using a molecular imaging system, a medical physicist determines the index of accumulation of radioisotope in lacrimal pathways. Based on the data obtained, the overall risk level of secondary obliteration of the lacrimal tract is determined and, depending on the result obtained, appropriate recommendations are made to the patient. Since the described process is quite time-consuming in a clinical setting, an intelligent medical decision support system has been developed that allows automating the process and minimizing the likelihood of errors. CONCLUSION: The development of a software and hardware preventive complex will make it possible to prescribe preventive methods with greater efficiency at all stages of the course of treatment in order to minimize the occurrence of adverse events (such as secondary obliteration of the tear ducts), which in turn will improve the quality of life of patients.

  • Open Access

    The lacrimal apparatus as an organ at risk during radionuclide therapy

    by M. S. Sheremeta, A. A. Trukhin, V. D. Yartsev, D. V. Yudakov, M. O. Korchagina, S. A. Gojaeva

    Within the framework of the article, the authors analyzed the available information about the damage to the lacrimal apparatus during radionuclide therapy. In focus of article lesions of the lacrimal production system, the main and accessory lacrimal glands, as well as lacrimal drainage are considered. It was found that damage to the lacrimal apparatus is characteristic of 131I therapy for thyroid cancer, as well as for radioligand therapy using anti-PSMA antibodies labeled with 177Lu and 225Ac. 177Lu-PSMA and 225Ac-PSMA may damage the lacrimal gland with the formation of a clinically pronounced "dry eye syndrome". The pathogenesis of such lesions is associated with the accumulation of a radioisotope in the tissues of the lacrimal apparatus, while during therapy with 131I, accumulation is realized due to the expression of the sodium-iodine symporter in the nasolacrimal duct, and during therapy with 177Lu-PSMA and 225Ac-PSMA, the radiobiological effect is realized in connection with the expression PSMA by lacrimal tissue. An analysis of the available sources showed that to date there are no results of systematic studies on the problem, there is a lack of knowledge regarding the individual risks of developing these complications, methods for their prevention that have proven effectiveness have not been developed, and the treatment methods used, having relatively low efficiency, are not specialized. The authors concluded that the strengthening of interdisciplinary interaction, as well as the organization verification methodology and correct studies, can contribute to solving problems related to the study of the complications under consideration.


  • Open Access

    Nasolacrimal Duct Obstruction Secondary to Radioactive Iodine-131 Therapy for Differentiated Thyroid Cancer

    by A. A. Trukhin, V. D. Yartsev, M. S. Sheremeta, D. V. Yudakov, M. O. Korchagina, R. Kh. Salimkhanov, S. V. Grishkov

    Вторичная облитерация слезоотводящих путей при проведении радиойодтерапии 131 I дифференцированного рака щитовидной железы


  • Open Access

    From physics to medicine, fundamentalist Leonidas D. Marinelli

    by D. V. Yudakov, S. P. Bondarenko, A. A. Trukhin

    От физики до медицины. Фундаменталист Леонидас Д. Маринелли